ContractTermination and Transition Services Agreement • July 15th, 2020
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
TERMINATION AND TRANSITION SERVICES AGREEMENTTermination and Transition Services Agreement • October 14th, 2022 • New York
This Termination and Transition Services Agreement (this “Agreement”) is made and entered into on August 15, 2022 (the “Execution Date”) by and among (a) IMMUNOMEDICS, INC., a company organized under the laws of the state of Delaware (“Immunomedics”) and a wholly-owned subsidiary of Gilead Sciences, Inc. (“Gilead”), (b) EVEREST MEDICINES II LIMITED, an exempt company organized under the laws of the Cayman Islands (“Everest Medicines II”), (c) EVEREST MEDICINES (SINGAPORE) PTE. LTD. (“Everest Singapore”, together with Everest Medicines II, “Everest”), and (d) solely with respect to Sections 1.1, 1.2 and 13.19, EVEREST MEDICINES LIMITED, an exempt company organized under the laws of the Cayman Islands (“Everest Parent”). Each of Immunomedics and Everest is referred to individually as a “Party” and collectively as the “Parties.”
